CoChat

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Open access
Fang, Fang, VanCleave, Ashley, Helmuth, Ralph, Torres, Haydee, Rickel, Kirby, Wollenzien, Hannah, Sun, Hongli, Zeng, Erliang, Zhao, Jing, Tao, Jianning · 2018 · Oncotarget
Cited by 69

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Fang Fang 1 , Ashley VanCleave 1 , Ralph Helmuth 1, 2 , Haydee Torres 1, 3 , Kirby Rickel 1, 4 , Hannah Wollenzien 1, 5 , Hongli Sun 6 , Erliang Zeng 7 , Jing Zhao 8, 9 and Jianning Tao 1, 3, 5, 10 1 Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD, USA 2 BRIN Scholar from Dakota Wesleyan University, Sanford Research, Sioux Falls, SD, USA 3 Department of Chemistry and Biochemistry, South Dakota State University, Brookings, SD, USA 4 Department of Biomedical Engineering, University of South Dakota, Sioux Falls, SD, USA 5 Basic Biomedical Sciences, University of South Dakota, Vermillion, SD, USA 6 Department of Oral and Maxillofacial Surgery, University of Iowa, Iowa City, IA, USA 7 Departments of Preventive & Community Dentistry, Biomedical Engineering, and Biostatistics, Division of Biostatistics and Computational Biology of College of Dentistry, University of Iowa, Iowa City, IA, USA 8 Population Health Group, Sanford Research, Sioux Falls, SD, USA 9 Department of Internal Medicine, University of South Dakota, Sioux Falls, SD, USA 10 Department of Pediatrics, University of South Dakota, Sioux Falls, SD, USA Correspondence to: Jianning Tao, email: Jianning.Tao@SanfordHealth.Org Keywords: osteosarcoma; Wnt/β-catenin signaling; PRI-724; Cyclin D1 Received: August 26, 2018 Accepted: November 07, 2018 Published: December 04, 2018 ABSTRACT Aberrant activation of Wnt signaling has been implicated in human osteosarcoma, which may provide a genetic vulnerability that can be targeted in osteosarcoma treatment. To test whether Wnt activation is necessary for osteosarcoma growth, colony formation, invasion, and metastasis, we treated human osteosarcoma cells with a small molecule inhibitor of Wnt/β-catenin, PRI-724, which suppresses Wnt/β-catenin-mediated transcription. We found increased protein levels of endogenous active-β-catenin in five human osteosarcoma cell lines. Treatment with PRI-724 was sufficient to inhibit human osteosarcoma 143B and SJSA-1 cell proliferation. Suppressed Wnt signaling was confirmed by decreased protein levels of the Wnt target Cyclin D1. Furthermore, we revealed significant inhibitory effects on cell migration, invasion, and colony formation in the human osteosarcoma cells. Using deposited data from next generation sequencing studies, we analyzed somatic mutations and gene expression of components in the Wnt/β-catenin pathway. We found somatic mutations and upregulated gene expression of many components in the Wnt/ β-catenin pathway, indicating activated Wnt signaling. Taken together, our results illustrate the critical role of Wnt/β-catenin signaling in human osteosarcoma pathogenesis and growth, as well as the therapeutic potential of Wnt inhibitors in the treatment of human osteosarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.26377

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 69

Metadata

Authors
Fang, F., VanCleave, A., Helmuth, R., Torres, H., Rickel, K., Wollenzien, H., Sun, H., Zeng, E., Zhao, J., & Tao, J.
Venue
Oncotarget
Published
2018-12-04
Volume
9
Issue
95
Pages
36780-36792
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2903208663
Cited by
69
References
12
FWCI
2.35
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.